The Long Run with Luke Timmerman
Ep149: Nancy Stagliano on Precision Neuroscience
Nov 29, 2023
Nancy Stagliano, CEO of Neuron23, discusses precision medicine in neuroscience drug discovery. Topics include genetic underpinnings of Parkinson's, studying neurodegeneration, transitioning from academia to biotech, challenges in drug discovery, focusing on Alzheimer's lead program, genetic links to neurological disorders, and future of targeted treatments.
01:01:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Precision medicine in neuroscience targets genetic mutations for tailored therapy in neurodegenerative diseases.
- Nancy Stagliano combines scientific expertise with business acumen to drive innovation in neurodegenerative treatments.
Deep dives
Neuron 23: Precision Neuroscience for Neurodegenerative Diseases
Neuron 23, a biotech company, aims to translate genetics into targeted therapies for Parkinson's, Alzheimer's, and other neurodegenerative diseases. Using a precision neuroscience approach, they target LARC2 protein associated with Parkinson's. A blood-based companion diagnostic helps select patients with the LARC2 genetic signature most likely to benefit from the drug. Neuron 23's focus on genetics and biomarkers provides hope for more effective treatments in neurodegenerative diseases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
